RA and cancer risk in the biologic era
Jun 02, 2023
Recent News
A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.Read Article
AI in RA: the story grows along the patient pathway
Jun 02, 2023
The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.
Read Article
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Jun 02, 2023
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Read Article
Using app for self-management in clinical care. There is a need to have continued engagement both patients and clinicians, constantly evolve the product, adapt to the changing needs of patients eg.pre and post pandemic, #WIIFM? @AurelieRheumo @ProfYelizPrior #EULAR2023 @RheumNow https://t.co/5RKog9EMsV
Jun 02, 2023
Metabolic Burden in the Early Stages of PsA
Dr. Aurelie Najm ( @AurelieRheumo )discusses abstract OP0066 presented at EULAR 2023 in Milan, Italy.
https://t.co/Z39ibke3JD https://t.co/YvWbNz9tFH
Links:
Jun 02, 2023
The #EULAR2023 wall is growing..@RheumNow https://t.co/tpJSp5Yc9X
Jun 02, 2023
Very interesting.
Overweight fibromyalgia pts had some sustained benefit of their fibro on a very low calorie ketogenic diet (8 weeks ketogenic, 12 weeks carb reintroduce)
Pain improvements matched weight loss. Many questions, I want to see more!
POS1339 #EULAR2023 @RheumNow https://t.co/3rIPmSVUwj
Jun 02, 2023
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Jun 02, 2023
✅Benefit of adding #HydroxyChloroquine #HCQ in refractory obstetric #APS
#EULAR2023 poster https://t.co/dgGY496dbh
Jun 02, 2023
Clinically suspect arthralgia-what is needed are predictors that enrich WHO will develop RA. Otherwise in 85% of Pts your (sham) Rx will work. If we need to reset the immune response- early makes sense but many will NOT have #RA over the next few yrs. @RheumNow #EULAR2023 https://t.co/vDv6cHqFUn
Jun 02, 2023
#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx
Jun 02, 2023
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity.
@rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Jun 02, 2023
Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease,
ACR1997 has the highest specificity both at diagnosis ans over time.
@RheumNow #EULAR2023 abst#POS0136
Jun 02, 2023
Factors associated with higher prevalence of post COVID-19 condition include female sex, age, asthma, diabetes, hypertension, number of symptoms in the acute phase and possible mechanisms causing the syndrome, Mayssam Nehme, COVID-19, #EULAR2023 https://t.co/IzHEQqfPb1
Jun 02, 2023
#EULAR2023 #OP0289 We need to improve health equity in the care of people with arthritis. An online survey showed that Black, Indigenous and People of Colour (BIPOC) Women in Canada faced a)unique & disproportionate barriers and b) complex experiences of discrimination @RheumNow https://t.co/hnahUIb9Xb
Jun 02, 2023
Predictors of myocarditis in anti-synthetase syndome - 43 pta 30% with myocarditis. More frequently males with high troponin levels. Only fever was more frequently observed in myocarditis pts. Pos1224 @rheumnow #EULAR2023
Jun 02, 2023
#Clinically suspect #arthralgia debate BE CAREFUL how you apply the criteria as sensitivity / specificity will vary if low pretest likelihood. @eular_org @RheumNow https://t.co/2XAwXbp1fi
Jun 02, 2023
Reflections on COVID-19 and autoimmunity: post-vaccination autoimmunity is not specific to COVID-19, autoimmunity is not autoimmune disease, the large numbers may result in the perception of increased occurrence of autoimmunity, Schulze-Koops H, COVID-19, #EULAR2023 @RheumNow https://t.co/Rm9OEWrBzo
Jun 02, 2023
« Science is a work of Art »
Yes it is.
If you are not convinced, have a look at this Twitter account that merges Van Gogh and #histology 👀
@RheumNow #EULAR23
👇🏼👇🏼👇🏼👇🏼 https://t.co/DEs8LXaCZ5
Jun 02, 2023
RheumNow’s expanded coverage of the #EULAR2023 Annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
Jun 02, 2023
#ClinicalPearls #rheumatoid #arthritis is changing. Less extra articulation and less mortality except ILD. Legacy pts exposed to ASA high dose, NSAIDs and injectable gold. We still see it rarely. @RheumNow #EULAR2023 @eular_org https://t.co/sC8vZkjO2x https://t.co/BFdpubei4u
Jun 02, 2023
From the blog
ICYMI: The Biosimilar "Buy In"
May 29, 2023
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients.
Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.
Read Post
Podcasts
TNR- Rheumatoid Arthritis - Decisive TherapeuticsMay 31, 2023
3 - 4-5 Rule (5.26.2023)May 26, 2023
TNR- Spondyloarthritis InnovationsMay 24, 2023
Therapeutic Updates
Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis
Sponsored by Janssen Biotech, Inc.
Jun 01, 2023
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.
Read Post
